MGP
CRL icon

Metis Global Partners’s Charles River Laboratories CRL Stock Holding History

Metis Global Partners’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$201K Buy
+886
New +$158K ﹤0.01% 686
2026
Q1 		– Sell
-1,068
Closed -$213K – 733
2025
Q4 		$213K Buy
+1,068
New +$194K 0.01% 724
2025
Q1 		– Sell
-1,720
Closed -$318K – 793
2024
Q4 		$318K Buy
1,720
+72
+4% +$13.9K 0.01% 656
2024
Q3 		$325K Buy
1,648
+21
+1% +$4.36K 0.01% 656
2024
Q2 		$336K Sell
1,627
-8
-0.5% -$1.81K 0.01% 636
2024
Q1 		$443K Sell
1,635
-24
-1% -$5.73K 0.02% 580
2023
Q4 		$392K Sell
1,659
-209
-11% -$41.1K 0.02% 598
2023
Q3 		$366K Buy
1,868
+346
+23% +$71K 0.02% 602
2023
Q2 		$320K Sell
1,522
-40
-3% -$7.96K 0.02% 609
2023
Q1 		$315K Buy
1,562
+505
+48% +$114K 0.02% 584
2022
Q4 		$230K Buy
+1,057
New +$231K 0.02% 578
2022
Q2 		– Sell
-799
Closed -$227K – 544
2022
Q1 		$227K Buy
+799
New +$246K 0.03% 507

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Metis Global Partners's CRL Position: Q2 2026 in Review

Metis Global Partners opened a new position in Charles River Laboratories (CRL) in Q2 2026: 886 shares worth $201K. The stake represents ﹤0.01% of the portfolio and ranks #686 among its holdings. This is a return to the name: Metis Global Partners previously reported a position in CRL as recently as Q4 2025.

Metis Global Partners first reported a position in CRL in Q1 2022 and has held it in 12 quarters since. The position peaked at $443K in Q1 2024. 563 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Metis Global Partners held 886 shares of Charles River Laboratories worth $201K as of Q2 2026.
  • Charles River Laboratories was a new Metis Global Partners position in Q2 2026.
  • Charles River Laboratories made up ﹤0.01% of Metis Global Partners's portfolio in Q2 2026, its #686 holding.
  • Metis Global Partners first reported a position in Charles River Laboratories in Q1 2022 and has held it in 12 quarters since.
  • Metis Global Partners's Charles River Laboratories position peaked at $443K in Q1 2024.
  • 563 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Metis Global Partners's 13F filing for Q2 2026, filed 10 Aug 2026.